Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Theranexus stock

ALTHX.PA
FR0013286259
A2H6LX

Price

0.49
Today +/-
+0.01
Today %
+2.48 %

Theranexus stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Theranexus stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Theranexus stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Theranexus stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Theranexus's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Theranexus Stock Price History

DateTheranexus Price
3/7/20250.49 undefined
3/6/20250.48 undefined
3/5/20250.50 undefined
3/4/20250.50 undefined
3/3/20250.50 undefined
2/28/20250.50 undefined
2/27/20250.50 undefined
2/26/20250.50 undefined
2/25/20250.51 undefined
2/24/20250.52 undefined
2/21/20250.52 undefined
2/20/20250.53 undefined
2/19/20250.52 undefined
2/18/20250.51 undefined
2/17/20250.51 undefined
2/14/20250.51 undefined
2/13/20250.51 undefined
2/12/20250.51 undefined
2/11/20250.51 undefined
2/10/20250.51 undefined
2/7/20250.54 undefined

Theranexus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Theranexus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Theranexus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Theranexus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Theranexus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Theranexus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Theranexus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Theranexus’s growth potential.

Theranexus Revenue, EBIT and net profit per share

DateTheranexus RevenueTheranexus EBITTheranexus Net Income
2026e0 undefined-7 M undefined-11.05 M undefined
2025e0 undefined-7.21 M undefined-9.83 M undefined
2024e0 undefined-7.21 M undefined-8.03 M undefined
20230 undefined-7.64 M undefined-6.83 M undefined
20220 undefined-6.26 M undefined-6.57 M undefined
20210 undefined-9.51 M undefined-8.15 M undefined
20200 undefined-6.1 M undefined-4.8 M undefined
20190 undefined-7.38 M undefined-5.58 M undefined
20180 undefined-6.99 M undefined-5.3 M undefined
20170 undefined-2.72 M undefined-2.11 M undefined
20160 undefined-2.06 M undefined-1.59 M undefined
2015566,500 undefined-1.12 M undefined-518,700 undefined

Theranexus Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e
000000000000
------------
------------
0000000-10000
0-1-2-5-5-4-8-6-6-8-9-11
--100.00150.00--20.00100.00-25.00-33.3312.5022.22
1.691.691.693.123.624.095.025.357.76000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Theranexus Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Theranexus is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
01.518.2315.179.4511.2112.539.114.9
00000264200
000001.772.0300
000000000
00.090.390.380.111.240.420.70.16
01.5918.6215.559.5614.2615.019.815.06
21.6000889.8646.5403.6168.15.8
017.7153.5147.192.8246.1150.5137.4112.2
000001.772.0300
00.340.530.941.912.321.321.221.15
000000000
000000000
0.020.360.681.092.894.993.91.531.27
0.021.9519.316.6412.4519.2418.9211.336.33
                 
00.420.780.780.911.021.261.341.94
02.1922.0222.0224.0412.515.628.364.02
0-930.6-2,517.4-4,632.2-9,932.9039.900
0-1.05-1.57-4.76-5.04-3.24-6.69-3.97-3.74
000000000
00.6318.7113.419.9810.2810.225.732.22
00.380.691.682.091.070.920.861.13
0107.7493.9289.9502346.8338.4492.6222.2
05.115.9000000
000000000
000000.81.1400
00.51.21.972.592.212.41.351.35
01.750.473.472.785.715.334.893.64
000000000
000021.466.484.589.124.8
01.750.473.472.85.775.414.983.67
02.251.665.445.397.987.816.335.02
02.8820.3818.8515.3718.2718.0312.057.24
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Theranexus provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Theranexus's financial health and stability.

Assets

Theranexus's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Theranexus must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Theranexus after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Theranexus's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20152016201720182019202020212022
0-1-2-5-5-4-8-6
0000001,0000
00000000
00000001,000
00000000
00000000
00000000
0-1-1-5-4-5-6-5
0000-2000
0000-2000
00000000
00000000
01-130300
002002480
011821771
00000001,000
00000000
0016-3-511-3
-0.87-1.64-2.04-5.87-7.07-5.93-6.3-5.45
00000000

Theranexus stock margins

The Theranexus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Theranexus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Theranexus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Theranexus's sales revenue. A higher gross margin percentage indicates that the Theranexus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Theranexus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Theranexus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Theranexus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Theranexus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Theranexus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Theranexus Margin History

Theranexus Gross marginTheranexus Profit marginTheranexus EBIT marginTheranexus Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %-197.07 %-91.56 %

Theranexus Stock Sales Revenue, EBIT, Earnings per Share

The Theranexus earnings per share therefore indicates how much revenue Theranexus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Theranexus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Theranexus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Theranexus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Theranexus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Theranexus Revenue, EBIT and net profit per share

DateTheranexus Sales per ShareTheranexus EBIT per shareTheranexus Earnings per Share
2026e0 undefined0 undefined-1.42 undefined
2025e0 undefined0 undefined-1.27 undefined
2024e0 undefined0 undefined-1.04 undefined
20230 undefined-0.99 undefined-0.88 undefined
20220 undefined-1.17 undefined-1.23 undefined
20210 undefined-1.89 undefined-1.62 undefined
20200 undefined-1.49 undefined-1.17 undefined
20190 undefined-2.04 undefined-1.54 undefined
20180 undefined-2.24 undefined-1.7 undefined
20170 undefined-1.61 undefined-1.25 undefined
20160 undefined-1.22 undefined-0.94 undefined
20150.34 undefined-0.66 undefined-0.31 undefined

Theranexus business model

Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus is one of the most popular companies on Eulerpool.com.

Theranexus SWOT Analysis

Strengths

Theranexus SA excels in its commitment to innovative research and development, continuously striving to discover novel therapeutic solutions for various diseases.

The company possesses a robust portfolio of intellectual property rights, providing a competitive advantage and ensuring protection of its innovative discoveries.

Theranexus SA benefits from a skilled and diverse team of professionals, comprising scientists, researchers, and industry experts, who contribute to the company's success through their expertise and collaboration.

Weaknesses

The company heavily relies on external funding sources for its research and development activities, which exposes it to potential financial uncertainties and limitations.

Theranexus SA currently has a limited presence in the market, making it challenging to establish brand recognition and gain significant market share compared to more established competitors.

Opportunities

As the demand for innovative therapies and personalized medicine increases, Theranexus SA has an opportunity to capitalize on this market trend by leveraging its research and development capabilities.

Collaborating with renowned pharmaceutical companies or research institutions can enable Theranexus SA to leverage their resources, expertise, and distribution channels, accelerating the commercialization of their products.

Threats

The biotechnology and pharmaceutical industry is highly competitive, with numerous players striving to develop breakthrough treatments. Theranexus SA faces the risk of competition from both established companies and emerging startups.

Compliance with ever-changing regulations and obtaining necessary approvals from regulatory authorities pose challenges and can potentially delay the launch of Theranexus SA's products, impacting its market position.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Theranexus Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Theranexus historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Theranexus shares outstanding

The number of shares was Theranexus in 2024 — This indicates how many shares 7.759 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Theranexus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Theranexus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Theranexus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Theranexus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Theranexus.

Theranexus shareholders

%
Name
Stocks
Change
Date
11.57780 % Beyond Batten Disease Foundation898,437011/13/2024
7.44539 % Auriga Partners577,762011/13/2024
5.06544 % Supernova Invest393,078011/13/2024
4.09505 % Charveriat (Mathieu)317,776011/13/2024
4.09505 % Mouthon (Franck)317,776011/13/2024
1.60745 % Kreaxi124,738011/13/2024
1.24851 % Platford (Richard)96,884011/13/2024
0.38660 % ACA Asset management Company & Associés30,000012/31/2023
0 % Montpensier Arbevel, S.A.S.0-78,1253/31/2024
1

Theranexus Executives and Management Board

Mr. Franck Mouthon

Theranexus Executive Chairman of the Board (since 2017)
Compensation 346,856

Mr. Mathieu Charveriat

Theranexus Chief Executive Officer, Director (since 2023)
Compensation 308,607

Mr. Jerome Martinez

(51)
Theranexus Independent Director
Compensation 7,500

Mr. Thierry Lambert

(67)
Theranexus Administrative and financial director

Dr. Werner Rein

Theranexus Chief Medical Officer
1
2

Most common questions regarding Theranexus

What values and corporate philosophy does Theranexus represent?

Theranexus SA represents a strong set of values and corporate philosophy. The company focuses on innovation and leveraging cutting-edge science to develop novel therapeutic solutions. Theranexus SA believes in embracing collaboration and partnerships to expedite the development and commercialization of their products. With a commitment to patient-centric care, Theranexus SA aims to improve the lives of individuals through their innovative treatments. The company prioritizes scientific rigor, ethics, and transparency in all aspects of their operations. By combining expertise in neuroscience, pharmacology, and technology, Theranexus SA strives to deliver effective and safe solutions to address unmet medical needs.

In which countries and regions is Theranexus primarily present?

Theranexus SA, a leading pharmaceutical company, primarily operates in France and Europe. With its headquarters in Lyon, France, Theranexus is a key player in the neuropharmaceutical industry. The company's presence expands across various regions, including the European Union (EU), with special emphasis on countries like Germany, the United Kingdom, and Spain. Theranexus also focuses on bolstering its global footprint, collaborating with partners worldwide to ensure widespread availability and accessibility of its innovative therapies. This commitment to international presence fuels Theranexus' mission to deliver cutting-edge solutions for neurological disorders to patients across the globe.

What significant milestones has the company Theranexus achieved?

Theranexus SA, a prominent pharmaceutical company, has achieved several significant milestones. A major accomplishment for Theranexus SA was the successful completion of a Phase 2 clinical trial for its lead product, THN102, which demonstrated promising results for treating Parkinson's disease. Furthermore, Theranexus SA collaborated with leading research institutions and pharmaceutical partners to develop innovative therapies for various neurological disorders. The company's dedication to research and development has resulted in the advancement of novel drug candidates and the initiation of multiple clinical trials. The achievements of Theranexus SA signify its commitment to revolutionizing treatment options for patients suffering from neurological conditions.

What is the history and background of the company Theranexus?

Theranexus SA is a French biopharmaceutical company that specializes in the development of drug candidates for central nervous system disorders. Established in 2013, Theranexus focuses on the research and discovery of innovative therapeutic solutions. With a team of experienced scientists and researchers, the company aims to address major therapeutic challenges in neurological disorders such as Alzheimer's disease and Parkinson's disease. Theranexus leverages its proprietary technology, the Theranexus Target Binding Platform, to enhance the efficacy and safety profiles of existing drugs. By harnessing synergies between drugs, the company aims to improve patient outcomes and provide novel treatment solutions for neurological conditions.

Who are the main competitors of Theranexus in the market?

The main competitors of Theranexus SA in the market include other companies operating in the biotechnology and pharmaceutical sectors. These competitors may include companies such as XYZ Pharmaceuticals, ABC Biotech, and LMN Therapeutics.

In which industries is Theranexus primarily active?

Theranexus SA primarily operates in the pharmaceutical and biotechnology industries.

What is the business model of Theranexus?

The business model of Theranexus SA revolves around the development and commercialization of innovative therapeutic solutions for neurological disorders. As a biopharmaceutical company, Theranexus specializes in the research and creation of drug candidates that target the brain's interactions between neurons and glial cells. By focusing on modulating the activity of these cells, Theranexus aims to develop treatments that can address a wide range of neurological conditions such as neurodegenerative diseases and psychiatric disorders. Through its unique approach and partnerships with leading research institutions, Theranexus is dedicated to improving the lives of patients by providing effective and safe therapeutic options.

What is the P/E ratio of Theranexus 2025?

The Theranexus P/E ratio is -0.39.

What is the P/S ratio of Theranexus 2025?

The Theranexus P/S ratio is 0.

What is the Quality Investing of Theranexus?

The Quality Investing for Theranexus is 2/10.

What is the revenue of Theranexus 2025?

The revenue cannot currently be calculated for Theranexus.

How high is the profit of Theranexus 2025?

The expected Theranexus profit is -9.83 M EUR.

What is the business model of Theranexus

Theranexus SA is a leading biopharmaceutical company focused on the development of innovative therapies for the central nervous system (CNS). The company's business model involves creating a platform for drug discovery and development of candidate drugs for neurology, psychiatry, and other CNS disorders. Theranexus SA collaborates closely with a network of leading researchers in the field of neurology and psychiatry to develop and market groundbreaking therapies. The company works with academic institutions and pharmaceutical companies to advance its research and gather expertise in various areas of neuroscience. Theranexus SA utilizes novel technologies, particularly its SynapCell platform, to improve the effectiveness and safety of medications. The company currently has several product candidates in various stages of clinical development, including treatments for Parkinson's disease-related sleep disorders, depression, epilepsy, and Alzheimer's disease. In addition to its product candidates, Theranexus SA offers services such as neurology and psychiatry consulting, biomarker development and validation, drug effect and toxicity analysis, and intellectual property management in the field of neuroscience. Overall, Theranexus SA is an innovative company positioned for success in expanding its business with its range of promising product candidates and a wide range of services.

What is the Theranexus dividend?

Theranexus pays a dividend of 0 EUR distributed over payouts per year.

How often does Theranexus pay dividends?

The dividend cannot currently be calculated for Theranexus or the company does not pay out a dividend.

What is the Theranexus ISIN?

The ISIN of Theranexus is FR0013286259.

What is the Theranexus WKN?

The WKN of Theranexus is A2H6LX.

What is the Theranexus ticker?

The ticker of Theranexus is ALTHX.PA.

How much dividend does Theranexus pay?

Over the past 12 months, Theranexus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theranexus is expected to pay a dividend of 0 EUR.

What is the dividend yield of Theranexus?

The current dividend yield of Theranexus is .

When does Theranexus pay dividends?

Theranexus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theranexus?

Theranexus paid dividends every year for the past 0 years.

What is the dividend of Theranexus?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theranexus located?

Theranexus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theranexus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theranexus from 3/8/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/8/2025.

When did Theranexus pay the last dividend?

The last dividend was paid out on 3/8/2025.

What was the dividend of Theranexus in the year 2024?

In the year 2024, Theranexus distributed 0 EUR as dividends.

In which currency does Theranexus pay out the dividend?

The dividends of Theranexus are distributed in EUR.

All fundamentals about Theranexus

Our stock analysis for Theranexus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theranexus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.